logo
Too young for credit cards but too old for piggy bank change? Here's how to help your kid navigate a cashless world

Too young for credit cards but too old for piggy bank change? Here's how to help your kid navigate a cashless world

Globe and Mail6 hours ago

Sweden is home to many things: Nearly 100,000 lakes, a cozy fika coffee culture, and delightful words like kaffesugen (the intense desire to drink that coffee). But what doesn't Sweden have?
Much cash.
That's what Jessica Dickson and her family discovered when they recently vacationed there.
'They didn't accept cash anywhere. Anywhere at all,' said the Calgary-based aesthetician and mom of four. 'I had all this cash and couldn't use it.'
Although Sweden, an early proponent of digital payments, has recently backpedaled amid security concerns, it's not the only place moving toward a cashless society. Many European and Asian countries are doing the same – and Canada isn't far behind.
According to a study by Payments Canada, only 31 per cent of Canadians use cash for day-to-day purchases. And observers note that more and more businesses are posting 'no cash' or 'card only' signs in their storefronts. Even some school vending machines offer only a tap option.
So where does that leave children in the in-between years of, say, ages nine to 12 – too young to handle credit cards, Apple Pay and e-transfers, but too old to dump piggybanks to buy summertime popsicles?
'We are living in a digital world, which impacts this age group,' says Robin Taub, a chartered professional accountant and Toronto-based author of The Wisest Investment: Teaching Your Kids to Be Responsible, Independent and Money-Smart for Life. And unlike in the U.S., where 'venmo me' is a popular request, and many teens use Cash App or Greenlight, similar electronic payment options are less common in Canada, she says. 'It feels like a lot of families here are just cobbling it together on their own.'
If that is your experience, too, here are some tips from experts and financially savvy parents to help your family meet this particular money moment.
While it's not uncommon for some parents to give their kids supplementary cards attached to their own credit cards, that approach comes with the risk of abuse. Luckily, there are other ways to go.
One option is the RBC-backed MyDoh, a money management app designed for kids and parents. It allows parents to transfer funds to a digital or physical prepaid card, set spending limits and monitor transactions. Kids can use it for in-store and online purchases as long as the business takes Visa.
Bank cards and digital payments are the norm for teenagers today. And that's a good thing
For one-off situations – such as a trip to a theme park or stadium, many of which don't accept cash – try reloadable prepaid cards (the kind found at grocery stores and pharmacies). But keep in mind that most come with steep activation fees, so a $4.95 fee on a $50 card means your child will have only $45.05 to spend.
Some parents may prefer to open a bank account for their kids so they can get them a debit card. If you decide to go this route, be sure to set up a weekly or transaction limit, advises Kevin Maynard, vice president and chief operating officer for the Canadian Foundation for Economic Education. Without those boundaries, their babysitting savings could go in an instant.
And if their account is attached to yours, turn on notifications, adds Maynard. Primarily used as a tool to thwart fraudsters and thieves, alerts will also help you know if your child impulsively spent $250 on flashy shoes.
'It's a very simple process. And you know exactly what's happening,' he says.
Just be aware that a financial institution might have numerous restrictions, including giving a younger child a debit card. Jessica Glazer, who runs a headhunting business in Montreal, recently experienced this situation with her 13-year-old son. At first her bank refused him a debit card because they worried he might blow through the money he'd saved from his bar mitzvah, even though he planned to invest it with his mom.
'I was like, 'But I need him to have a bank card for when he needs to buy a bus pass or whatever. There are certain things he needs a bank card for,'' said Glazer.
The bank eventually gave it to him.
Whether you go with a prepaid card or a debit card for your kid, it's important to talk about ground rules in advance, says Taub.
Will your kids have to ask permission before purchasing anything, or only above a certain threshold? What will the repercussions be for breaking rules? And if a card is to be used for emergencies only, what exactly does that mean?
'Because some kids will try to rationalize that going out with their friends is some kind of emergency,' says Taub. 'Conversations need to be had.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?
GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?

Globe and Mail

time3 hours ago

  • Globe and Mail

GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?

GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, regulatory and pipeline successes and an optimistic outlook for the long term are the key factors driving the increase amid several headwinds like slowing sales in the Vaccines unit, generic competition for some drugs and broader economic pressure. Let's discuss these factors in detail to understand how to play GSK's stock amid the recent price increase. GSK Specialty Medicines Unit on a Strong Footing GSK is witnessing increased sales growth of its Specialty Medicines unit, particularly reflecting successful new launches in Oncology and long-acting HIV medicines. Sales are rising in all areas, HIV, Immunology/Respiratory as well as Oncology. Sales of the Specialty Medicines unit rose 19% in 2024, driven by double-digit growth in all therapy areas. The positive trend continues in 2025 with sales rising 17% in the first quarter of 2025. In the segment, while products like Nucala and Dovato are key top-line drivers, new long-acting HIV medicines, Cabenuva and Apretude, as well as new oncology drugs Jemperli and Ojjaara, are also witnessing strong patient demand and contributing to top-line growth. In 2025, the company expects sales in the Specialty Medicines segment to rise in a low double-digit percentage at CER, despite the impact from the Inflation Reduction Act or IRA. Specialty Medicines, which now accounts for around 40% of GSK's sales, is expected to be more than 50% of GSK's total revenue by 2031. GSK's Promising Pipeline GSK is increasing R&D investment in promising new long-acting and specialty medicines in Respiratory, Immunology & Inflammation, Oncology and HIV areas. GSK's pentavalent MenABCWY meningococcal vaccine and Blujepa/gepotidacin for treating uncomplicated urinary tract infection ('UTI') were approved in the United States in the first quarter of 2025. Its blockbuster drug Nucala was approved for treating chronic obstructive pulmonary disease or COPD, its fifth indication, in May 2025. Regulatory applications seeking approval of the Blenrep combination for relapsed/refractory multiple myeloma and depemokimab for two indications (chronic rhinosinusitis with nasal polyps or CRSwNP and asthma with type II inflammation) are under review in the United States and some other countries. FDA decisions on all these filings are expected in 2025. Blenrep combinations were approved in the United Kingdom and Japan in April/May 2025. In 2025, GSK expects to launch five new products/line extensions, including Blenrep, depemokimab (severe asthma and CRSwNP), Nucala for COPD, Penmenvy and Blujepa. Of these, Penmenvy, Blujepa and Nucala for COPD are already approved in the United States. GSK's Vaccine Sales Slowing Down GSK's first-quarter Vaccine sales declined 6% due to lower sales of its RSV vaccine, Arexvy, and shingles vaccine, Shingrix. U.S. sales of Shingrix declined 21% in the first quarter of 2025 due to lower demand as a result of challenges in activating harder-to-reach consumers. Arexvy's global sales declined 57% in the first quarter. Revised recommendations for RSV vaccinations issued in June 2024 by the U.S. Advisory Committee on Immunization Practices (ACIP) have been hurting sales of Arexvy from the second half of 2024 in the United States. In June, the ACIP recommended the use of Arexvy for all adults aged 75 and above. However, for adults aged 60-74, the ACIP recommended the vaccine only for those who are at increased risk of severe RSV disease. A challenging macro environment in China and potential for changes in vaccination policies in the United States are expected to hurt Vaccine sales in the near term. In 2025, the company expects sales in the Vaccines segment to decline by a low single-digit percentage at CER. GSK's Price Performance, Valuation & Estimate Movement GSK stock has risen 20.1% year to date compared with an increase of 4.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. The stock has also been trading above 200 and 50-day moving averages since May. GSK Stock Outperforms Industry, Sector and S&P GSK's stock is trading at an attractive valuation relative to the industry. Going by the price/earnings ratio, the company's shares currently trade at 8.63 on a forward 12-month basis, lower than 15.63 for the industry. The stock also trades below its 5-year mean of 10.25. The stock is much cheaper than several other large drugmakers like Eli Lilly LLY, Novo Nordisk NVO, AbbVie ABBV and AstraZeneca. GSK Stock Valuation Image Source: Zacks Investment Research The Zacks Consensus Estimate for earnings has risen from $4.26 to $4.42 per share for 2025 and from $4.71 to $4.82 per share for 2026 over the past 60 days. GSK's Estimates Stay Invested in GSK Stock GSK has its share of problems. Competitive pressure on HIV and respiratory drugs has risen. The dolutegravir HIV franchise patent expires in the 2028-2029 period, and U.S. vaccine sales are slowing down. In 2025, GSK also expects a negative sales impact of £400-500 million due to the impact of the IRA Medicare Part D redesign. However, the company is consistently growing its sales and profits, mainly driven by its Specialty Medicines segment. For the five-year period till 2026, GSK expects to record more than 7% sales growth while core operating profit is expected to increase more than 11% on a CAGR basis. In this period, Specialty Medicines is expected to rise in the low-to-mid teens percentage while General Medicines is expected to rise by a low single-digit percentage. The growth in Specialty Medicines and improvement in General Medicines are making up for a slowdown in the Vaccines unit. The company also resolved the vast majority of Zantac litigations in 2024, which had long been an overhang on the stock. GSK believes it is well-positioned to navigate and mitigate the potential financial impact of tariffs on pharmaceutical imports through supply chain and increased productivity initiatives We suggest investors who own this Zacks Rank #3 (Hold) stock stay invested for now, considering steady sales and profit improvement in the coming years. Consistently rising estimates also reflect analysts' optimistic outlook for future growth in profits. Buying the stock at its present cheap valuation can prove prudent for long-term investors who are interested in buying blue-chip companies. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report

Nvidia Stock Forecast: Can You Afford to Miss the Next Big Breakout?
Nvidia Stock Forecast: Can You Afford to Miss the Next Big Breakout?

Globe and Mail

time3 hours ago

  • Globe and Mail

Nvidia Stock Forecast: Can You Afford to Miss the Next Big Breakout?

Nvidia (NVDA) is once again capturing Wall Street's attention as its stock edges closer to a new all-time high. After a strong 2% gain on Monday and a powerful rebound in recent weeks, investors are wondering, could a new all-time high record be just days away? Confident Investing Starts Here: What's Behind the Recent Surge? On Monday, Nvidia shares advanced nearly 2% to close at $144.69. The gain extends the company's strong 2025 performance, with the stock already rising 7.74% year-to-date after over 170% gain in 2024. The rally began after Nvidia delivered stellar Q1 results in May, reigniting investor optimism. Meanwhile, recent momentum was supported by last week's GTC Paris event and CEO Jensen Huang's appearance at France's Viva Technology conference. 'Sovereign AI' took the spotlight during Huang's recent tour of Europe, as leaders across the region rallied behind the push to develop country-specific AI infrastructure, including data centers, computing power, and tailored software stacks. Overall, Nvidia continues to see strong demand, driven by global markets building out sovereign AI capabilities. Additionally, the conference spotlighted AI use cases in Europe, especially in automotive and robotics, with BMW (DE:BMW) and Volkswagen (DE:VOW) showcased as key adopters. Nvidia's focus on established industrial players highlighted its regional strategy beyond startups. What's Next for Investors? Looking ahead, Wall Street analysts maintain a strongly bullish stance on Nvidia. Recently, Oppenheimer's five-star-rated analyst Rick Schafer reiterated his Buy rating on NVDA stock. Schafer predicts an upside of 21% from the current levels. Schafer believes Nvidia is in the strongest position to lead the AI space, thanks to its full-stack hardware and software solutions. Earlier, Bernstein analyst Stacy Rasgon reiterated a Buy rating on Nvidia, projecting a 28% upside. He believes the recent challenges have already been factored into the stock's valuation, suggesting further gains are possible if Nvidia successfully navigates current restrictions. Rasgon also emphasized that Nvidia's data center opportunity is 'enormous' and still in its early growth phase. What Is the 12-month Price Target for Nvidia? According to TipRanks, NVDA stock has a Strong Buy consensus rating based on 35 Buys, four Holds, and one Sell assigned in the last three months. At $172.36, the Nvidia average share price target implies a 19% upside potential. See more NVDA analyst ratings

28 Strategy Execution and Evolves its Executive Committee
28 Strategy Execution and Evolves its Executive Committee

National Post

time3 hours ago

  • National Post

28 Strategy Execution and Evolves its Executive Committee

Article content PARIS — , a global leader in Testing, Inspection, and Certification services (TIC) is accelerating the execution of its LEAP | 28 strategy to reach its vision of being the preferred partner for its customers' excellence and sustainability. Taking LEAP | 28 to the next level, Bureau Veritas is evolving the structure of its executive committee to drive greater organizational alignment, strengthening its geographical platform with scalable Product Line structures, and optimizing its operations to enhance agility and effectiveness. Since the strategy launch in March 2024, LEAP | 28 strategy execution has progressed steadily in all three pillars – Portfolio, Performance & People – and is now reaching an important stage requiring an evolution of the operating model. The new structure will empower the regions with scalable Product Lines, enabling global offers development, unlocking greater cross-selling opportunities, and driving growth and profitability. Article content The current six operating geographical Regions will be reorganized into four greater Regions: Americas, Europe, Asia Pacific, Middle East Caspian & Africa. The Product lines will be managed under three executive committee members who will lead: Industrials and Commodities, Urbanization and Assurance, and Consumer Products Services. These groupings at the executive committee level are aligned with customer workflows and market needs. Article content Article content Considering the company ambition to scale performance programs across all the Regions and Product lines, a Chief Performance Officer and Executive Committee member role will be dedicated to lead the LEAP I 28 performance pillar and the overall optimization of key performance functions of operational excellence & performance, and sales & marketing. This role will drive the design, governance, and overall implementation and monitoring of these programs in coordination with other stakeholders across the organization. Article content 'By directly connecting Product Lines to a simplified regional structure, we are strengthening our regional expertise and building deeper relations with our customers. This organization will also allow us to create more agility as we accelerate the execution of our LEAP | 28 strategy. Article content This new organization will leverage scale, benefit from a well-defined structure, thus speeding up decision making, performance impact, and innovation. I fully trust our Bureau Veritas Executive team to mobilize the entire organization to achieve our vision and deliver on our ambition.' Article content The transition period will extend from July 1 st to the end of August 2025. Effective September 1 st 2025, the Group Executive Committee will be structured and composed as follows: Article content Product Lines: Article content Industrials and Commodities: Executive Vice-President > Matthieu Gondallier De Tugny Urbanization and Assurance: Executive Vice-President > Marc Roussel Consumer Products Services: Executive Vice-President > Catherine Chen Article content Business Functions: Article content Corporate development & sustainability: Executive Vice-President > Juliano Cardoso Chief Performance Officer: Executive Vice-President > Laurent Louail Chief Digital & Innovation Officer: Executive Vice-President DxT (Digital & Technology) > Philipp Karmires Article content Support Functions: Article content *** Article content About Bureau Veritas Article content Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress. With a vision to be the preferred partner for customers' excellence and sustainability, the company innovates to help them navigate change. Created in 1828, Bureau Veritas' 84,000 employees deliver services in 140 countries. The company's technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability. Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40, CAC 40 ESG, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI. For more information, visit and follow us on LinkedIn. Article content *** Article content Biographies: Article content Vincent Bourdil, Article content appointed Executive Vice-President, Europe, joined Bureau Veritas in 2016 and has held multiple leadership roles across the company. His most recent roles were Executive Vice-President, Global Business Lines & Performance before becoming Executive Vice-President, Commodities, Industry & Facilities, Southwest Europe. Article content Khurram Majeed Article content remains Executive Vice-President, Middle East, Caspian & Africa. He is a seasoned industry leader with over 23 years of senior management experience across energy, oil & gas, and other sectors. Khurram joined Bureau Veritas in 2024 as Executive Vice-President, Middle East, Caspian & Africa. Article content Surachet Tanwongswal Article content remains Executive Vice-President Asia Pacific. He joined Bureau Veritas in 2024 as Executive Vice-President for Commodities, Industry & Facilities in Asia Pacific. Prior to this, Surachet held leadership roles at Ecolab and other global B2B companies. Article content Matthieu Gondallier de Tugny, Article content appointed Executive Vice-President Industrials and Commodities, joined Bureau Veritas in 1994 and has held various technical, operational, and leadership roles in Marine & Offshore. His most recent role was Executive Vice-President, Marine & Offshore. Article content Marc Roussel, Article content appointed Executive Vice-President Urbanization and Assurance, joined Bureau Veritas in 2015 and has held multiple leadership roles across the company. His most recent role was Executive Vice-president, Commodities, Industry & Facilities, France. Article content Catherine Chen Article content remains Article content Article content Executive Vice-President Consumer Products Services. She joined Bureau Veritas in 2005 and has held various sales, marketing, and operational leadership roles in Consumer Product Services. Catherine will continue to connect Consumer Products & Technology Product Lines, as Executive Vice-President, Consumer Products Services. Article content Laurent Louail, Article content appointed Executive Vice-President Chief Performance Officer, joined Bureau Veritas in 1995 and has held multiple leadership roles across the company. His most recent roles were Executive Vice-President, Commodities, Industry & Facilities in Southwest Europe, before becoming Executive Vice-President, Global Business Lines & Performance. Article content Juliano Cardoso Article content remains Executive Vice-President Corporate Development & Sustainability. He joined Bureau Veritas in 1999 and has held leadership roles across the company. Juliano will continue to lead our corporate development and sustainability efforts in his current role as Executive Vice-President, Corporate Development & Sustainability. Article content Philipp Karmires Article content remains Executive Vice-President Chief Digital & Innovation Officer. He is a senior executive with over 20 years of experience in digital transformation, enterprise software and product innovation. Philipp joined Bureau Veritas in 2024 and will continue to lead the DxT (Digital & Technology) function as Executive Vice-President, Chief Digital & Innovation Officer. Article content François Chabas Article content remains Executive Vice-President Chief Financial Officer. He joined Bureau Veritas in 2003, holding finance roles with increasing responsibility before becoming Chief Financial Officer in 2014. François will continue to lead the finance function as Executive Vice-President, Finance. Article content Maria Lorente Fraguas Article content remains Article content Article content Executive Vice-President Chief People Officer. She joined Bureau Veritas in 2024 after holding senior operational and human resources roles in international companies across multiple countries. Maria will continue to lead the people function as Executive Vice-President, Chief People Officer. Article content Article content Executive Vice-President Legal & Internal Audit. She joined Bureau Veritas in 2020 after serving as general counsel for other companies in France. Béatrice will continue to lead the legal and compliance function as Executive Vice-President, Legal affairs & Internal Audit. Article content Article content Article content Article content Article content Contacts Article content ANALYST/INVESTOR CONTACTS Article content Article content Laurent Brunelle Article content Article content +33 (0)1 55 24 76 09 Article content Article content Article content Colin Verbrugghe Article content Article content +33 (0)1 55 24 77 80 Article content Article content Article content MEDIA Anette Rey Article content Article content +33 (0)6 69 79 84 88 Article content Article content Article content Martin Bovo Article content Article content +33 (0) 6 14 46 79 94 Article content Article content Article content Karine Ansart Article content Article content Article content Article content

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store